These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The mechanism of insulin-stimulated 4E-BP protein binding to mammalian target of rapamycin (mTOR) complex 1 and its contribution to mTOR complex 1 signaling. Rapley J; Oshiro N; Ortiz-Vega S; Avruch J J Biol Chem; 2011 Nov; 286(44):38043-38053. PubMed ID: 21914810 [TBL] [Abstract][Full Text] [Related]
3. Regulation of proline-rich Akt substrate of 40 kDa (PRAS40) function by mammalian target of rapamycin complex 1 (mTORC1)-mediated phosphorylation. Wang L; Harris TE; Lawrence JC J Biol Chem; 2008 Jun; 283(23):15619-27. PubMed ID: 18372248 [TBL] [Abstract][Full Text] [Related]
4. Mechanisms of mTORC1 activation by RHEB and inhibition by PRAS40. Yang H; Jiang X; Li B; Yang HJ; Miller M; Yang A; Dhar A; Pavletich NP Nature; 2017 Dec; 552(7685):368-373. PubMed ID: 29236692 [TBL] [Abstract][Full Text] [Related]
5. PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Sancak Y; Thoreen CC; Peterson TR; Lindquist RA; Kang SA; Spooner E; Carr SA; Sabatini DM Mol Cell; 2007 Mar; 25(6):903-15. PubMed ID: 17386266 [TBL] [Abstract][Full Text] [Related]
6. AKT inhibition overcomes rapamycin resistance by enhancing the repressive function of PRAS40 on mTORC1/4E-BP1 axis. Mi W; Ye Q; Liu S; She QB Oncotarget; 2015 Jun; 6(16):13962-77. PubMed ID: 25961827 [TBL] [Abstract][Full Text] [Related]
7. A dual mTORC1 and mTORC2 inhibitor shows antitumor activity in esophageal squamous cell carcinoma cells and sensitizes them to cisplatin. Huang Y; Xi Q; Chen Y; Wang J; Peng P; Xia S; Yu S Anticancer Drugs; 2013 Oct; 24(9):889-98. PubMed ID: 23838676 [TBL] [Abstract][Full Text] [Related]
8. Rapamycin attenuates BAFF-extended proliferation and survival via disruption of mTORC1/2 signaling in normal and neoplastic B-lymphoid cells. Zeng Q; Qin S; Zhang H; Liu B; Qin J; Wang X; Zhang R; Liu C; Dong X; Zhang S; Huang S; Chen L J Cell Physiol; 2018 Jan; 233(1):516-529. PubMed ID: 28300280 [TBL] [Abstract][Full Text] [Related]
9. Overexpression of PRAS40(T246A) in the Proliferative Compartment Suppresses mTORC1 Signaling, Keratinocyte Migration, and Skin Tumor Development. Rho O; Srivastava J; Cho J; DiGiovanni J J Invest Dermatol; 2016 Oct; 136(10):2070-2079. PubMed ID: 27349859 [TBL] [Abstract][Full Text] [Related]
10. S6K1 regulates hematopoietic stem cell self-renewal and leukemia maintenance. Ghosh J; Kobayashi M; Ramdas B; Chatterjee A; Ma P; Mali RS; Carlesso N; Liu Y; Plas DR; Chan RJ; Kapur R J Clin Invest; 2016 Jul; 126(7):2621-5. PubMed ID: 27294524 [TBL] [Abstract][Full Text] [Related]
11. mTORC1 and mTORC2 regulate insulin secretion through Akt in INS-1 cells. Le Bacquer O; Queniat G; Gmyr V; Kerr-Conte J; Lefebvre B; Pattou F J Endocrinol; 2013 Jan; 216(1):21-9. PubMed ID: 23092880 [TBL] [Abstract][Full Text] [Related]
12. [Research progress in PRAS40]. Chen G; Zhu G; Zhang X Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2018 Jun; 43(6):685-690. PubMed ID: 30110013 [TBL] [Abstract][Full Text] [Related]
13. Role of PRAS40 in Akt and mTOR signaling in health and disease. Wiza C; Nascimento EB; Ouwens DM Am J Physiol Endocrinol Metab; 2012 Jun; 302(12):E1453-60. PubMed ID: 22354785 [TBL] [Abstract][Full Text] [Related]
14. Conditional Disruption of Raptor Reveals an Essential Role for mTORC1 in B Cell Development, Survival, and Metabolism. Iwata TN; Ramírez JA; Tsang M; Park H; Margineantu DH; Hockenbery DM; Iritani BM J Immunol; 2016 Sep; 197(6):2250-60. PubMed ID: 27521345 [TBL] [Abstract][Full Text] [Related]
15. A functional mammalian target of rapamycin complex 1 signaling is indispensable for c-Myc-driven hepatocarcinogenesis. Liu P; Ge M; Hu J; Li X; Che L; Sun K; Cheng L; Huang Y; Pilo MG; Cigliano A; Pes GM; Pascale RM; Brozzetti S; Vidili G; Porcu A; Cossu A; Palmieri G; Sini MC; Ribback S; Dombrowski F; Tao J; Calvisi DF; Chen L; Chen X Hepatology; 2017 Jul; 66(1):167-181. PubMed ID: 28370287 [TBL] [Abstract][Full Text] [Related]
16. Point mutations of the mTOR-RHEB pathway in renal cell carcinoma. Ghosh AP; Marshall CB; Coric T; Shim EH; Kirkman R; Ballestas ME; Ikura M; Bjornsti MA; Sudarshan S Oncotarget; 2015 Jul; 6(20):17895-910. PubMed ID: 26255626 [TBL] [Abstract][Full Text] [Related]
17. ATP-site binding inhibitor effectively targets mTORC1 and mTORC2 complexes in glioblastoma. Neil J; Shannon C; Mohan A; Laurent D; Murali R; Jhanwar-Uniyal M Int J Oncol; 2016 Mar; 48(3):1045-52. PubMed ID: 26719046 [TBL] [Abstract][Full Text] [Related]
18. Reciprocal regulation of mTOR complexes in pancreatic islets from humans with type 2 diabetes. Yuan T; Rafizadeh S; Gorrepati KD; Lupse B; Oberholzer J; Maedler K; Ardestani A Diabetologia; 2017 Apr; 60(4):668-678. PubMed ID: 28004151 [TBL] [Abstract][Full Text] [Related]